Revefenacin, a Once-Daily, Lung-Selective, Long-Acting Muscarinic Antagonist for Nebulized Therapy: Safety and Tolerability Results of a 52-Week Phase 3 Trial in Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Respiratory Medicine - United Kingdom

doi 10.1016/j.rmed.2019.05.010